Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma

Ann Oncol. 2010 Jun;21(6):1385-1387. doi: 10.1093/annonc/mdq153.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Antineoplastic Agents / therapeutic use
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Mutation / physiology
  • Neoplasm Metastasis
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins p21(ras)
  • Quinazolines / therapeutic use*
  • Remission Induction
  • Time Factors
  • ras Proteins / genetics*

Substances

  • Antineoplastic Agents
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • Quinazolines
  • Erlotinib Hydrochloride
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins